249 related articles for article (PubMed ID: 29545055)
1. Imaging the High-risk Prostate Cancer Patient: Current and Future Approaches to Staging.
Bjurlin MA; Turkbey B; Rosenkrantz AB; Gaur S; Choyke PL; Taneja SS
Urology; 2018 Jun; 116():3-12. PubMed ID: 29545055
[TBL] [Abstract][Full Text] [Related]
2. State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer.
Schiavina R; Chessa F; Borghesi M; Gaudiano C; Bianchi L; Corcioni B; Castellucci P; Ceci F; Ceravolo I; Barchetti G; Del Monte M; Campa R; Catalano C; Panebianco V; Nanni C; Fanti S; Minervini A; Porreca A; Brunocilla E
Int J Urol; 2019 Jan; 26(1):18-30. PubMed ID: 30238516
[TBL] [Abstract][Full Text] [Related]
3. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
4. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
5. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
6. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
BJU Int; 2012 Nov; 110(10):1501-6. PubMed ID: 22502982
[TBL] [Abstract][Full Text] [Related]
7.
Metser U; Berlin A; Halankar J; Murphy G; Jhaveri KS; Ghai S; Tau N
AJR Am J Roentgenol; 2018 Mar; 210(3):635-640. PubMed ID: 29323548
[TBL] [Abstract][Full Text] [Related]
8. Imaging of distant metastases of prostate cancer.
Pesapane F; Czarniecki M; Suter MB; Turkbey B; Villeirs G
Med Oncol; 2018 Sep; 35(11):148. PubMed ID: 30218382
[TBL] [Abstract][Full Text] [Related]
9. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
10. The role of 18F-flourocholine PET/CT in biochemically relapsed prostate cancer: a case of osteolytic prostate metastasis.
Tabrizipour AI; Dunne M
Clin Nucl Med; 2015 May; 40(5):e285-6. PubMed ID: 25608148
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
Ferraro DA; Burger IA
Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
[TBL] [Abstract][Full Text] [Related]
12. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
13. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
14. (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study.
Fonager RF; Zacho HD; Langkilde NC; Petersen LJ
BMC Cancer; 2016 Jan; 16():10. PubMed ID: 26753880
[TBL] [Abstract][Full Text] [Related]
15. How does endorectal MRI, PET-CT and transrectal ultrasound contribute to diagnosis and management of localized prostate cancer.
Rincón Mayans A; Diaz-Tejeiro BZ; Rioja Zuazu J; Díaz Dorronsoro L; Rodriguez Fraile M; Boillos AB; Bergera JZ
Arch Esp Urol; 2011 Oct; 64(8):746-64. PubMed ID: 22052757
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
17. [Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment].
Cochet A; Kanoun S; Humbert O; Walker PM; Cormier L; Créhange G; Brunotte F
Cancer Radiother; 2014 Oct; 18(5-6):509-16. PubMed ID: 25195114
[TBL] [Abstract][Full Text] [Related]
18. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement.
Van den Bergh L; Lerut E; Haustermans K; Deroose CM; Oyen R; Isebaert S; Budiharto T; Ameye F; Mottaghy FM; Bogaerts K; Van Poppel H; Joniau S
Urol Oncol; 2015 Mar; 33(3):109.e23-31. PubMed ID: 25655681
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic relevance of choline-PET / CT in patients with prostate cancer].
Zengerling F; Schrader AJ; Schrader M; Jentzmik F
Aktuelle Urol; 2012 Jan; 43(1):49-54. PubMed ID: 21769763
[TBL] [Abstract][Full Text] [Related]
20. Imaging of Prostate Cancer Using Fluciclovine.
Savir-Baruch B; Zanoni L; Schuster DM
PET Clin; 2017 Apr; 12(2):145-157. PubMed ID: 28267449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
